Darodipine

Research use only, not for human use.

Darodipine is a dihydropyridine type Ca+2 antagonist.

Darodipine is a dihydropyridine type Ca+2 antagonist.(In Vivo):Darodipine may reduce neuronal cytoskeletal changes occurring in aging and in neurodegenerative disorders. Darodipine (10 mg/kg; 6-month (from the 18th to the 24th month of life); p.o.) treatment restores in part the expression of 200 kDa-NF subunit immunoreactivity in the cerebellar cortex. Treatment with darodipine increases the number and the average length of alkaline phosphatase-reactive capillaries and reduces the intercapillary distance and the diameter of cerebral capillaries in old rats. The pericapillary microrenvironment of the Ammon’s horn is the most sensitive to treatment with darodipine.

——

Treatment with darodipine increases the number and the average length of alkaline phosphatase-reactive capillaries and reduces the intercapillary distance and the diameter of cerebral capillaries in old rats. The pericapillary microrenvironment of the Ammon’s horn is the most sensitive to treatment with darodipine. Darodipine may reduce neuronal cytoskeletal changes occurring in aging and in neurodegenerative disorders. A 6-month treatment (from the 18th to the 24th month of life) with an oral daily dose of 10 mg/kg of darodipine restores in part the expression of 200 kDa-NF subunit immunoreactivity in the cerebellar cortex.

PY 108-068 | PY-108068

GPCR/G Protein

Calcium Channel

mAChR

——

——

72803-02-2

371.393

C19H21N3O5

>98% (HPLC)

——

CCOC(=O)C1=C(C)NC(C)=C(C1c1cccc2nonc12)C(=O)OCC

——

(-20℃)

With Ice Pack

≥ 2 years